Table 3

Baseline characteristics by treatment assignment

Treatment group
ControlHydration
n=11n=18
Mean age, years (SD)67 (11)59 (14)
Men (%)6467
Caucasian (%)9178
Weight, kg (SD)86 (19)92 (22)
Body mass index, kg/m2 (SD)30 (6)31 (6)
Waist circumference (cm)110 (11)101 (18)
Smoking status (%)
 Current011
 Former7353
Primary diagnosis of chronic kidney disease (%)
 Diabetes4617
 Hypertension2717
 Polycystic kidney disease017
 Unknown/other3650
Comorbidities (%)
 Cerebrovascular/TIA96
 Coronary artery disease96
 Hypertension10077
 Diabetes6447
 Peripheral vascular disease276
 Hyperlipidaemia7353
 Gastric bleeding180
 COPD96
 Malignancy012
Mean blood pressure, mm Hg (SD)
 Systolic143 (17)140 (22)
 Diastolic73 (11)80 (11)
Heart rate, bpm (SD)80 (11)80 (13)
eGFR, mL/min/1.73 m2 (SD)39 (11)41 (10)
Hematocrit, L/L (SD)0.39 (0.05)0.40 (0.06)
HbA1c (SD)0.07 (0.02)0.07 (0.01)
Medications (%)
 Aspirin4622
 ACE/ARB inhibitors6467
 Diuretics8228
 Calcium channel blockers4622
 Beta blockers2717
 Angiotensin II receptor blockers4617
 Vasopressor06
 Statin6444
First degree relative with hypertension or kidney failure4661
  • ACE/ARB, angiotensin-converting enzyme/angiotensin receptor blockers; COPD, chronic obstructive pulmonary disorder; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; TIA, transient ischemic attack..